HomeReprieve Cardiovascular

Reprieve Cardiovascular

Reprieve Cardiovascular™ Announces New Clinical Study Results TARGET II Study

Professor Piotr Ponikowski, Professor of Cardiology at Wroclaw Medical University, 4th Military Hospital in Wroclaw, Poland, presented early positive results from the TARGET II Study.

RenalGuard Solutions Debuts Newly Formed Reprieve Cardiovascular at Heart Failure Society of America Annual Meeting and Completes $7 Million Financing

9/12/18: Reprieve Cardiovascular will demonstrate its innovative Guided Diuretic Therapy at the Heart Failure Society of America’s 22nd Annual Scientific Meeting in Nashville, Tennessee, beginning September 15, 2018.